- Home
- XCUR vs DYAI Comparison
XCUR vs DYAI Comparison
Compare XCUR & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- DYAI
- Stock Information
- Founded
- XCUR 2011
- DYAI 1979
- Country
- XCUR United States
- DYAI United States
- Employees
- XCUR N/A
- DYAI N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XCUR Health Care
- DYAI Health Care
- Exchange
- XCUR Nasdaq
- DYAI Nasdaq
- Market Cap
- XCUR 32.4M
- DYAI 30.2M
- IPO Year
- XCUR N/A
- DYAI 2004
- Fundamental
- Price
- XCUR $4.23
- DYAI $1.16
- Analyst Decision
- XCUR
- DYAI Strong Buy
- Analyst Count
- XCUR 0
- DYAI 1
- Target Price
- XCUR N/A
- DYAI $6.00
- AVG Volume (30 Days)
- XCUR 30.7K
- DYAI 139.0K
- Earning Date
- XCUR 11-13-2025
- DYAI 11-11-2025
- Dividend Yield
- XCUR N/A
- DYAI N/A
- EPS Growth
- XCUR N/A
- DYAI N/A
- EPS
- XCUR N/A
- DYAI N/A
- Revenue
- XCUR N/A
- DYAI $4,135,078.00
- Revenue This Year
- XCUR N/A
- DYAI $34.23
- Revenue Next Year
- XCUR N/A
- DYAI $19.57
- P/E Ratio
- XCUR N/A
- DYAI N/A
- Revenue Growth
- XCUR N/A
- DYAI 129.20
- 52 Week Low
- XCUR $2.15
- DYAI $0.71
- 52 Week High
- XCUR $36.00
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- XCUR 44.40
- DYAI 56.82
- Support Level
- XCUR $4.12
- DYAI $1.13
- Resistance Level
- XCUR $4.57
- DYAI $1.35
- Average True Range (ATR)
- XCUR 0.34
- DYAI 0.10
- MACD
- XCUR 0.15
- DYAI 0.00
- Stochastic Oscillator
- XCUR 70.56
- DYAI 50.16
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.